Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureNicolas Girard
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer
10.1200/jco.21.01308 · 2022
Treatment characteristics and real-world progression-free survival in patients with unresectable Stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study
10.1016/j.jtho.2022.10.003 · 2023
ctDNA-Based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab
10.1016/j.jtho.2026.103992 · 2026
Predictive effectiveness of circulating tumor DNA in recurrent early-stage non-small cell lung cancer: an updated meta-analysis
2025
CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC
2024
10.1016/j.annonc.2025.09.081
10.1016/j.annonc.2025.09.081 · 2025
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer
10.1080/14796694.2024.2354160 · 2024
Rationale and design of the Phase III KEYLYNK-012 study of pembrolizumab and concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for Stage III non-small-cell lung cancer
10.1016/j.cllc.2022.04.003 · 2022
De-escalation strategies with immune checkpoint blockers in non-small cell lung cancer: do we already have enough evidence?
10.1200/jco-24-02347 · 2025
Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: a retrospective validation study
10.1371/journal.pmed.1004574 · 2025
First-line camizestrant for emerging ESR1-mutated advanced breast cancer
10.1056/nejmoa2502929 · 2025
No additional external references are available.